Arquivo de Pesquisa Mitocondrial


Uma biblioteca selecionada de publicações científicas revisadas por pares que exploram as fronteiras da energia celular, da resiliência metabólica e da ciência da vitalidade humana.

Human Pharmacokinetic Study of Purified (−)-Epicatechin

Study Title: Pharmacokinetic, partial pharmacodynamic and initial safety analysis of (−)-epicatechin in healthy volunteers

Citation: Barnett et al., 2015 · Food & Function

What the Study Found: This phase I, open-label human study evaluated purified (−)-epicatechin in healthy volunteers. Participants received single oral doses of 50, 100, or 200 mg, or repeated 50 mg doses once or twice daily for 5 days. The researchers measured absorption, metabolism, early safety, and selected biological markers related to nitric oxide signaling, mitochondrial enzyme activity, and muscle-related pathways.

The authors reported that purified (−)-epicatechin was rapidly absorbed and metabolized, with several metabolites detected in blood. After repeated dosing, the study observed changes in selected biomarkers, including plasma nitrite, platelet mitochondrial enzyme activity, and follistatin measures. No adverse effects attributed to (−)-epicatechin were reported in this small short-term study.

What this means in real life: This study helps distinguish purified (−)-epicatechin from cocoa, dark chocolate, or mixed flavanol products. It shows that purified (−)-epicatechin can be absorbed and measured in humans, and that it may influence biological pathways connected to nitric oxide signaling, vascular biology, mitochondrial enzyme activity, and muscle-related signaling.

These findings are preliminary. The study did not test whether (−)-epicatechin improves fatigue, exercise performance, recovery, cardiovascular outcomes, or any disease condition. Larger and longer clinical trials would be needed to evaluate those questions.

Clinical Relevance: Human phase I pharmacokinetic and partial pharmacodynamic study in healthy volunteers; purified (−)-epicatechin, nitric oxide metabolites, platelet mitochondrial enzyme activity, and follistatin signaling; not a randomized efficacy trial and not evidence that (−)-epicatechin treats, prevents, or cures disease.

Related Content: